Production of tPA Using Both Eukaryotic Cells (CHO) And Prokaryotic Cells (E. Coli)

Answer 1

The case study is unique because it describes the advancement in recombinant-DNA technology that allows production of proteins which are therapeutically active and the production is efficient in unlimited quantities. This case study discusses the production of recombinant tissue plasminogen activator (rtPA) in Chinese hamster ovary and in Escherichia coli. The case study also discusses the comparison between the both as each system produces a product different in characteristics and the production process if also different. The focus remains that production of rtPA shows a significant reduction in ...